envelope protein

(-)-JNJ-A07 is a selective and potent dengue virus (DENV) inhibitor with an EC50 of 31 nM, exhibiting significant antiviral activity for the study of dengue virus infections.

TBMP (butylated hydroxyanisole) is the viral envelope protein hemagglutinin (HA)-mediated entry novel inhibitor.

NBD-556 is a small molecule mimetic of CD4. NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.

BMS-585248 is a highly effective HIV-1 adhesion inhibitor that targets the viral envelope protein gp120.

EOS is a ceramide found in the outer layer of the epidermis in mammals. It is comprised of an ω-hydroxy very long-chain ceramide (C28-36) esterified to the essential fatty acid linoleic acid . The consecutive regio- and stereospecific oxygenation of the linoleate portion of EOS by 12(R)-lipoxygenase (12(R)-LO) and eLOX3 is essential for the maintenance of the epidermal barrier to prevent water loss. Following oxygenation, the oxidized linoleate is hydrolyzed, leaving the ω-hydroxy end of the very long-chain fatty acid to covalently bind the protein layer, forming the corneocyte lipid envelope and sealing the gap between the extracellular lipid lamellae and the cornified cell envelope of the corneocyte.

Defensin HNP-3 is a peptide secreted by human polymorphonuclear leukocytes (PMNs) that has antimicrobial properties. It induces lysis of mammalian cells when used at a concentration of 25 μg/mL. It also inhibits growth of E. faecalis (ED50 = 100 nM) and clinical isolates of P. aeruginosa (MIC90 = 4 μM). HNP-3 binds to recombinant HIV-1 envelope glycoprotein (gp120) and human CD4 (Kds = 52.8 and 34.9 nM, respectively). It also binds to recombinant, immobilized human surfactant protein D (SP-D; Kd = 55.7 nM) and inhibits focus formation in Madin-Darby canine kidney (MDCK) cells infected with influenza A virus (IAV).

HCV-1 e2 Protein (554-569), a primary antigenic region within the Hepatitis C Virus envelope 2 (e2) protein, contains a putative N-glycosylation site believed to affect immune recognition of e2 [1].

HCV-1 e2 Protein (484-499) is a 16-amino acid peptide derived from the envelope 2 protein of the hepatitis C virus, identified in the sera of individuals possessing antibodies to HCV [1].

HBV Seq2 aa:208-216, a CD8 epitope peptide derived from HBsAg, is investigated within the context of the Large envelope protein from the Hepatitis B virus [1].

Wulfenioidin F, a diterpenoid isolated from the whole plant of Orthosiphon wulfenioides, exhibits anti-Zika virus (ZIKV) activity with an EC50 of 8.07 μM and hinders virus replication by inhibiting the expression of the ZIKV envelope (E) protein [1].

Wulfenioidin H (Compound 5), a diterpenoid, demonstrates anti-Zika virus (ZIKV) activity by inhibiting the expression of the ZIKV envelope (E) protein, resulting in an effective concentration ( EC_{50} ) value of 8.50 μM [1].

HCV-1 e2 Protein (554-569) TFA, an antigenic segment of the hepatitis C virus envelope 2 (e2) protein, contains a potential N-glycosylation site that may influence immune recognition of e2 [1].

Tobevibart, an IgG1-lambda humanized monoclonal antibody targeting the hepatitis B virus (HBV) surface envelope protein, exhibits antiviral activity [1].

F9170, an antiviral peptide derived from the HIV-1 envelope glycoprotein (amino acids 789-803), targets the LLP1 domain in the virus's envelope protein cytoplasmic tail. This interaction inhibits HIV-1 IIIB infection in MT-2 cells, evidenced by an EC50 value of 0.19 µM. Additionally, at a dosage of 3 mg/kg, F9170 significantly lowers plasma viral load in rhesus macaques infected with simian HIV (SHIV).

VRC-01 is a human-derived IgG1 antibody that targets the envelope glycoprotein gp120 protein [gp120]. By partially mimicking the interaction between the CD4 receptor and the HIV-1 gp120 envelope glycoprotein, VRC-01 inhibits viral entry. For the isotype control of VRC-01, refer to HumanIgG1kappa, Isotype Control.

matrix protein (3-15) [Zaire ebolavirus] is a peptide of the structural proteins linking the viral envelope with the zaire ebolavirus core. Ebola virus (EBOV) is a member of the family Filoviridae in the order Mononegavirales. It is the causative agent of

MLH40 is a peptide inhibitor that acts against dengue virus (DENV) infection. It was identified in the conserved external domain of the DENV membrane protein. MLH40 inhibits DENV by interacting with the N-terminal loop of the DENV envelope protein, thereby altering the dimer conformation.